C12Y 306/03044
Xenobiotic-transporting atpase
Official title: Xenobiotic-transporting ATPase (3.6.3.44)
C12Y306/03044 (Xenobiotic-transporting atpase) appears on 7 US grants and 8 published applications in this corpus.
Search patents in C12Y- Granted patents
- 7
- Published applications
- 8
- Assignees
- 8
- Inventors
- 12
- Latest grant
- 20 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 0 |
| 2017 | 2 | 2 |
| 2018 | 0 | 1 |
| 2019 | 2 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)20 Jan 2026US 12,528,808 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Stable gene transfer to proliferating cells7 Jun 2022US 11,351,272 B2Children's Medical Research Institute
- Immune modulator for immunotherapy and vaccine formulation11 Jun 2019US 10,316,072 B2Health Research, Inc.
- Oligopeptidic compounds and uses thereof26 Feb 2019US 10,213,483 B2Apim Therapeutics AS
- Immune modulator for immunotherapy and vaccine formulation21 Nov 2017US 9,822,154 B2Health Research, Inc.
- A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)11 Aug 2022US 2022/0249473 A1University of Pittsburgh-of the Commonwealath System of Higher Education
- Stable gene transfer to proliferating cells16 Jan 2020US 2020/0016278 A1Children's Medical Research Institute
- Immune modulator for immunotherapy and vaccine formulation19 Apr 2018US 2018/0105562 A1Health Research, Inc.
- Oligopeptidic compounds and uses thereof31 Aug 2017US 2017/0246248 A1Apim Therapeutics AS
- Stable Gene Transfer to Proliferating Cells3 Aug 2017US 2017/0216456 A1
Most cited
By later US patents